Stock Profile: A2 Milk

Most people will have seen, heard or tried A2 Milk at some stage. It's probably healthier than regular milk as it doesn't contain the A1 protein which can cause adverse digestive symptoms for some. So why is this 'healthy' milk such a good investment proposition?

Stock Profile

Stock Profile: A2 Milk

April 6, 2020
Most people will have seen, heard or tried A2 Milk at some stage. It's probably healthier than regular milk as it doesn't contain the A1 protein which can cause adverse digestive symptoms for some. So why is this 'healthy' milk such a good investment proposition?
Read Transcript

Jun Bei Liu, from Tribeca Investment Partners presented A2 Milk at the 2019 Sohn Hearts & Minds Investment Conference. Last year she presented New Oriental Education, which proved to be one of the outstanding picks for HM1, delivering the fund a return of 60% in 4 months. Needless to say, we were excited to have Jun Bei back and have her pitch her latest high conviction idea.

Most people will have seen, heard or tried A2 Milk at some stage. It's in all of our supermarkets and corner stores, and many new mums have given their babies one of the A2 Protein Infant formulas. The difference between A2 milk and regular cows milk is the presence of the A1 protein in regular milk, which may cause adverse digestive symptoms in certain individuals.

The A2 Milk Company is the successor of A2 Corporation Limited, a New Zealand company founded in 2000 by Dr Corran McLachlan, who was researching the health effects of A1 beta-casein, and Howard Paterson, a significant dairy farmer, and a stakeholder in Fonterra, a dairy cooperative. The company commercialised a genetic test to determine whether a cow will produce milk without the A1 protein, and to market A1 protein-free milk.

Ok, so I get that A2 milk is probably healthier than regular milk, but why does Jun Bei think it is such a great investment proposition?

China.

Jun Bei told the audience that A2 is taking advantage of a multi decade thematic to leverage off the world's largest consumer market. With a population of 1.4 billion people, she sees 250 million (10x the entire Australian population) people moving into the upper middle income bracket, with families spending more and more on children's education (New Oriental) and their nutrition. 

15 million babies are born in China each year, and the majority of them are fed infant formula from birth to 5 years of age, which is very different to Western culture. Infant formula is a $24b market already, and Jun Bei is seeing an increased shift towards premium brands. The infant formula premium brands have doubled their market share in the past 2 years. A2 is one of the top ten online selling brands in China.

Revenue has grown eleven-fold in the last 5 years, and earnings (based on EBITDA) have grown from $3m to $400m during that same period, and its balance sheet is extremely strong.

Even with recent broker upgrades, she still thinks there is 30% upside to the share price over the next 12 months.

How?

A2 are already doing well in their online business in China, but they are also one of the few Australian companies to have a licence to physically sell their products in Chinese stores. They currently sell in over 16,500 stores across China, and she believes this will grow to over 30,000 stores within 5 years. If A2 can replicate the success of their online business in the physical stores, and the US business continues to grow, she believes that revenue could easily triple again.

She concluded by explaining that while on some of the more traditional metrics A2 may appear expensive, when you price the stock relative to its earnings growth, it remains one of the most attractive investment opportunities in the Australian market.

 

A2 Milk Company Ltd: Company Details

Ticker code: A2M AU

Market Capitalisation: $12.3bn

Average Daily Volume: 4.6 million shares / daily

52 week range: $11.28 - $17.30

Bloomberg consensus: 9 Buys, 4 Holds, 2 Sells

Price target: $17.09

 

A2 Milk Company Ltd: Share Price History

A2M-SHARE-PRICE

 

Jun Bei Liu, from Tribeca Investment Partners presented A2 Milk at the 2019 Sohn Hearts & Minds Investment Conference. Last year she presented New Oriental Education, which proved to be one of the outstanding picks for HM1, delivering the fund a return of 60% in 4 months. Needless to say, we were excited to have Jun Bei back and have her pitch her latest high conviction idea.

Most people will have seen, heard or tried A2 Milk at some stage. It's in all of our supermarkets and corner stores, and many new mums have given their babies one of the A2 Protein Infant formulas. The difference between A2 milk and regular cows milk is the presence of the A1 protein in regular milk, which may cause adverse digestive symptoms in certain individuals.

The A2 Milk Company is the successor of A2 Corporation Limited, a New Zealand company founded in 2000 by Dr Corran McLachlan, who was researching the health effects of A1 beta-casein, and Howard Paterson, a significant dairy farmer, and a stakeholder in Fonterra, a dairy cooperative. The company commercialised a genetic test to determine whether a cow will produce milk without the A1 protein, and to market A1 protein-free milk.

Ok, so I get that A2 milk is probably healthier than regular milk, but why does Jun Bei think it is such a great investment proposition?

China.

Jun Bei told the audience that A2 is taking advantage of a multi decade thematic to leverage off the world's largest consumer market. With a population of 1.4 billion people, she sees 250 million (10x the entire Australian population) people moving into the upper middle income bracket, with families spending more and more on children's education (New Oriental) and their nutrition. 

15 million babies are born in China each year, and the majority of them are fed infant formula from birth to 5 years of age, which is very different to Western culture. Infant formula is a $24b market already, and Jun Bei is seeing an increased shift towards premium brands. The infant formula premium brands have doubled their market share in the past 2 years. A2 is one of the top ten online selling brands in China.

Revenue has grown eleven-fold in the last 5 years, and earnings (based on EBITDA) have grown from $3m to $400m during that same period, and its balance sheet is extremely strong.

Even with recent broker upgrades, she still thinks there is 30% upside to the share price over the next 12 months.

How?

A2 are already doing well in their online business in China, but they are also one of the few Australian companies to have a licence to physically sell their products in Chinese stores. They currently sell in over 16,500 stores across China, and she believes this will grow to over 30,000 stores within 5 years. If A2 can replicate the success of their online business in the physical stores, and the US business continues to grow, she believes that revenue could easily triple again.

She concluded by explaining that while on some of the more traditional metrics A2 may appear expensive, when you price the stock relative to its earnings growth, it remains one of the most attractive investment opportunities in the Australian market.

 

A2 Milk Company Ltd: Company Details

Ticker code: A2M AU

Market Capitalisation: $12.3bn

Average Daily Volume: 4.6 million shares / daily

52 week range: $11.28 - $17.30

Bloomberg consensus: 9 Buys, 4 Holds, 2 Sells

Price target: $17.09

 

A2 Milk Company Ltd: Share Price History

A2M-SHARE-PRICE

 

Disclaimer: This material has been prepared by Hearts & Minds Investments, published on Apr 06, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 11, 2022

Sohn Hearts & Minds with Nick Griffin and Maggie O'Neill

Maggie O'Neill, HM1's Head of Marketing and Operations joined Nick Griffin, CIO of Munro Partners to discuss Hearts & Minds' history, Munro Partners' involvement and Nick's upcoming stock pitch.

Read More
December 2, 2021

Hearts and Minds 2021: Buying is only half the battle

Patrick Poke from Livewire reviews some of the stocks held by HM1 and pitched at the 2020 Sohn Hearts & Minds Conference.

Read More
February 23, 2021

Podcast: Chris Cuffe, Inside the Rope

Get to know our Chairman. In this episode, Chris Cuffe shares his background in funds management, his current portfolio of roles and some of the key lessons he's learnt.

Read More
November 30, 2020

Equity Mates x HM1

We've partnered with Equity Mates Media, Australia's number one finance and investing podcast, to do a series of interviews with our Fund Managers. For easy listening, all of 2020 episodes are here in one place.

Read More
October 22, 2020

Equity Mates: Rory Lucas

Our CIO Rory Lucas recently sat down with the Equity Mates Podcast to talk all things Hearts and Minds.

Read More
September 18, 2020

Commsec Executive Series: Paul Rayson (HM1)

CEO Paul Rayson discusses our unique model on CommSec's Executive Series, highlighting our strong performance, support of Australian medical research, and our upcoming virtual conference on Nov 13.

Read More
July 21, 2020

Hearts and Minds but no ratings

HM1 CIO, Rory Lucas recently spoke with the Financial Standard about our 12-month performance and the challenges in receiving ratings from the major research houses.

Read More
May 18, 2020

What does NTA mean, and what's the difference between the 3 numbers?

We explain what NTA stands for, what it means for investors and what the difference between the three NTA numbers we publish.

Read More
March 6, 2020

Stock Profile: Spotify

Spotify is an instantly recognisable brand for most. It's a leader in the audio space and can be thanked for saving the music industry from the internet piracy threat of the early 2000’s. So why is Spotify Hamish Corlett's highest conviction stock?

Read More
Hearts and Minds director Gary Weiss at the Sohn Hearts and Minds Investment Conference last November. Picture: David Geraghty.Hearts and Minds director Gary Weiss at the Sohn Hearts and Minds Investment Conference last November. Picture: David Geraghty.Hearts and Minds director Gary Weiss at the Sohn Hearts and Minds Investment Conference last November. Picture: David Geraghty.Hearts and Minds director Gary Weiss at the Sohn Hearts and Minds Investment Conference last November. Picture: David Geraghty.
June 28, 2019

Hearts and Minds Investments lifts value

Hearts and Minds Investments has increased in value by 20 per cent since listing last November and now has an net asset value of $600 million.

Read More
November 14, 2018

Hearts and Minds LIC starts trading on ASX after strong support

Media Release: HM1 starts trading on the ASX after closing its $500 million IPO early and bringing forward the company's listing date.

Read More
November 13, 2018

Hearts and Minds: Aiming to make a positive impact

Millennials are leading a global investment revolution, driving a change in how the super-rich invest their money. Ethical and sustainable investing is booming and poised to accelerate.

Read More
October 22, 2018

Charitable LIC reaches offer target early – Close of General Offer

HM1, a new listed investment company with performance and charitable goals, has closed its general offer early following strong market support.

Read More
October 15, 2018

Chris Cuffe: Investing with Hearts and Minds

It’s not often that an opportunity presents itself where you can both make money and contribute to a good cause. Hearts and Minds is one such opportunity.

Read More
October 15, 2018

Win-Win for investors and charities as top funds join forces for good

Australia’s top fund managers have joined forces in the name of medical research and today announce the opening of the IPO for Hearts and Minds Investments Limited.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.